Request Trial
lsipr-oct-13-page-40
16 October 2013Big PharmaBethan Hopewell and Geraldine Quinn

'Because he fears': should generics fear the high court's quia timet injunctions?

In July 2013, the English High Court gave its judgment in an action brought by patentee Merck Sharp & Dohme, and its exclusive licensee Bristol-Myers Squibb (BMS), against generic pharmaceutical manufacturer Teva.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026   Otsuka v Sun Pharma could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in the country.
Big Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026   Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.
Big Pharma
Novo Nordisk and OpenAI strike AI deal to boost drug discovery
15 April 2026   The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.


Editor's picks

What’s at stake in Australia’s biggest pharma patent appeal in years?
Big Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026

Editor's picks

Big Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026
Biotechnology
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
25 June 2026
Biotechnology
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Big Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

More features

LSD trade secrets suit over clinical trail info thrown out by judge
HGF expands European offering with pair of in-house hires
What’s at stake in Australia’s biggest pharma patent appeal in years?
Will Mounjaro and Zepbound get their first US generic rival?
Merck KGaA agrees $11.3bn deal in major life sciences expansion
Pfizer’s US Paxlovid patent fight turns on a single error
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
Novo secures website blocking to tackle fake weight-loss drugs